Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial. | J Clin Oncol;41(6): 1159-1160, 2023 02 20. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.

Stinchcombe, Thomas E.

Affiliation

Stinchcombe TE; Division of Medical Oncology, Duke Cancer Institute, Durham, NC.

J Clin Oncol ; 41(6): 1159-1160, 2023 02 20.

Article in En | MEDLINE | ID: mdl-36791472

Subject(s)

Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Humans; Carcinoma, Non-Small-Cell Lung/drug therapy; Gefitinib/therapeutic use; Lung Neoplasms/drug therapy; Methacrylates/therapeutic use; Antineoplastic Agents/therapeutic use

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article Affiliation country: New Caledonia

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Antineoplastic Agents Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article Affiliation country: New Caledonia